entospletinib + famotidine

This entry refers to the combination of **entospletinib**, a selective oral small molecule spleen tyrosine kinase (SYK) inhibitor primarily under investigation for hematological malignancies, and **famotidine**, an approved small molecule histamine H2 receptor antagonist widely used to inhibit gastric acid secretion for conditions such as ulcers, GERD, and hypersecretory states. While famotidine is known for its acid-suppressing properties, entospletinib’s mechanism involves blocking signal transduction in B-cell malignancies. The two drugs are not co-formulated but may be co-administered in clinical regimens or studied for drug-drug interactions. Certain co-administration issues may arise: famotidine can affect the absorption of drugs with pH-dependent solubility, but it is generally considered to have fewer interactions compared to stronger acid suppressants. For some kinase inhibitors, famotidine may need to be separated in timing to minimize reduction in drug efficacy.